- Home
- IONS vs OGS Comparison
IONS vs OGS Comparison
Compare IONS & OGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- OGS
- Stock Information
- Founded
- IONS 1989
- OGS 1906
- Country
- IONS United States
- OGS United States
- Employees
- IONS N/A
- OGS N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- OGS Oil/Gas Transmission
- Sector
- IONS Health Care
- OGS Utilities
- Exchange
- IONS Nasdaq
- OGS Nasdaq
- Market Cap
- IONS 5.4B
- OGS 4.7B
- IPO Year
- IONS 1991
- OGS N/A
- Fundamental
- Price
- IONS $33.51
- OGS $74.73
- Analyst Decision
- IONS Buy
- OGS Buy
- Analyst Count
- IONS 18
- OGS 7
- Target Price
- IONS $57.41
- OGS $75.64
- AVG Volume (30 Days)
- IONS 1.5M
- OGS 835.8K
- Earning Date
- IONS 04-30-2025
- OGS 05-05-2025
- Dividend Yield
- IONS N/A
- OGS 3.58%
- EPS Growth
- IONS N/A
- OGS 3.26
- EPS
- IONS N/A
- OGS 4.20
- Revenue
- IONS $717,253,000.00
- OGS $2,260,428,000.00
- Revenue This Year
- IONS $7.14
- OGS $24.59
- Revenue Next Year
- IONS $18.89
- OGS $4.08
- P/E Ratio
- IONS N/A
- OGS $17.82
- Revenue Growth
- IONS N/A
- OGS 7.73
- 52 Week Low
- IONS $23.95
- OGS $58.82
- 52 Week High
- IONS $52.34
- OGS $82.25
- Technical
- Relative Strength Index (RSI)
- IONS 56.80
- OGS 47.18
- Support Level
- IONS $32.00
- OGS $72.66
- Resistance Level
- IONS $33.65
- OGS $75.42
- Average True Range (ATR)
- IONS 1.08
- OGS 1.72
- MACD
- IONS -0.10
- OGS -0.16
- Stochastic Oscillator
- IONS 55.72
- OGS 59.59
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.